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Background
Thalidomide is an immunomodulating agent; although
its action mechanisms are not fully understood, many
authors have described its anti-inflammatory and immu-
nosuppressive properties with Peripheral Neuropathy
(PN) as a significant side effect, which may limit its clini-
cal use.
Methods
We describe a patient with JIA at systemic onset, partial
responding to etanercept, who presented a good control
of articular symptoms after thalidomide, but showed PN
after 16 months of therapy.
Results
Our patient, boy, 19 years old, 63.5 kg (50°centile), 161
cm, (3°centile), is affected by JIA, diagnosed at the age of
7 years. Since he presented many acute phases of illness,
though on therapy with immunosuppressant (methotrex-
ate 10 mg/m2/week), steroid and NSAID, in 2001 we
introduced an anti-TNF drug (etanercept 0.5 mg/kg/twice
a week) while reducing progressively steroid dose. How-
ever the patient showed still numerous articular acute
phases. We decided to associate thalidomide (100 mg/
die). After two months, the boy showed an improvement
of the articular symptoms. After six months JIA was in
remission. After 16 months of thalidomide therapy, he
presented electrophysiological PN, without clinical
signs;we decided to stop the thalidomide therapy. Now,
after 3 years of thalidomide suspension, no acute phases
of JIA were observed and an electrophysiological improve-
ment of PN was confirmed.
Conclusion
Our data show that thalidomide can be administered in
children with resistant forms of JIA, but a long-term
administration can significantly increase the risk of neuro-
toxicity [1]. A regular follow-up every 3 months is neces-
sary to identify and monitor possible side effects
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